Oxford Gene Technology

Executive Summary

Oxford Gene Technology (OGT) is a UK-based precision genomics company founded in 1995, specializing in hybridization-based FISH, NGS, and microarray products. The company enables clinical and research laboratories to interrogate key biomarkers for haematological malignancies, solid tumours, cytogenetics, and rare diseases. With a focus on accurate, patient-specific clinical decisions, OGT provides easy-to-use genetic analysis tools that support the growing demand for precision medicine. As a private company with a long-standing track record, OGT is well-positioned in the genomics diagnostics market, though it faces competition from larger players such as Illumina and Thermo Fisher. The company's comprehensive product portfolio and expertise in cytogenetics and oncology give it a unique niche, particularly in haematological cancers. Future growth is likely driven by expansion into liquid biopsy and NGS-based companion diagnostics, as well as strategic partnerships with pharmaceutical companies. However, as a private entity, OGT's financials and near-term milestones are not publicly disclosed, limiting visibility.

Upcoming Catalysts (preview)

• Q3 2026Launch of new NGS liquid biopsy panel for solid tumors70% success
• Q1 2027CE-IVD approval for a FISH-based hematology assay80% success
• Q2 2026Strategic partnership with a pharma company for companion diagnostics60% success